Front Page

Viewing related articles

Virtual face-to-face meetings extended as CGT celebrates its first successful virtual event

Virtual face-to-face meetings extended as CGT celebrates its first successful virtual event

Inaugural virtual face-to-face meeting a success We can confirm that the BioPhorum virtual collaboration model is delivering.  On Friday 6 March we decided to relocate CGT05 from Philadelphia to the cloud, and, from Tuesday 10, our team delivered a three-day meeting virtually.  As well as sharing case studies, delegates engaged in debates, periodically sharing webcams for a more personal experience. The attendance, representing 26 companies,...

read more
Regulatory compliance: what lessons can be learned?

Regulatory compliance: what lessons can be learned?

The person responsible for regulatory compliance (PRRC) is a new role, as defined in the European medical devices and in vitro diagnostic regulations. Interviews carried out by BioPhorum showed that most manufacturers are yet to appoint a PRRC. So, what are the requirements of this role and how should it be performed? New legal requirement The EU Medical Devices Regulation (MDR) (EU 2017/745) and In Vitro Diagnostic Regulation (IVDR) (EU...

read more
Biomanufacturing technology roadmap

Biomanufacturing technology roadmap

BioPhorum has produced a document on the technology and regulatory gaps in the continuous downstream processing of therapeutic proteins. The Continuous Downstream Processing For Biomanufacturing: An Industry Review paper uses a mAb process as a model system and highlights the gaps that are preventing the use of continuous biomanufacturing. It contains a gap analysis of a typical continuous mAb downstream process from primary capture to bulk...

read more
Driving progress in Cell & Gene Therapy

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C&GT) Phorum has made great strides since its formation in 2018. The Phorum has a growing list of goals for the next 12–18 months and the team will use its combined strength to accomplish these. The Phorum aims to support the faster delivery of C&GT products to market, by lowering business and supply chain risk, and accelerating...

read more
BioPhorum brings together industry leaders

BioPhorum brings together industry leaders

Held in Lausanne, Switzerland, in May, the annual BioPhorum meeting (BioPhorum 2019) attracted some 55 leaders from across the biopharmaceutical industry. With this year’s major theme being the digitalization of biomanufacturing, member companies Boehringer Ingelheim, GSK and Lonza each presented case studies, covering topics such as artificial intelligence in process development, virtual and augmented reality, 3D printing, smart glasses,...

read more
Changing mindsets with a modular approach

Changing mindsets with a modular approach

“We sense fear of the unknown… yes, the future may appear scary, but the future of our industry needs us to act now.” These are the words of Stefan Merkle, Senior Director Sterility Assurance at Janssen at last year’s Fill Finish Technologies to Reduce Drug Release Times event (FF18). While this comment was in relation to a discussion on whether to pursue in-line monitoring/real-time release (ILM/RTR) technologies, it is equally applicable to...

read more
The BioPhorum and USP collaborative journey to new standards

The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration. To this end, USP is engaging with industry to understand its pain points, its challenges and where there is the potential for new standards. “We have been looking at what additional standards we can develop that aren’t necessarily the traditional USP product-specific standards, but that would...

read more